Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease

International Journal of Neuropsychopharmacology

Volumn 18, Issue 6, 2015, Pages 1-11

  Drouin Ouellet, Janelle ^a   St Amour, Isabelle ^b   Saint Pierre, Martine ^b   Lamontagne Proulx, Jérôme ^b   Kriz, Jasna ^c,d   Barker, Roger A ^a   Cicchetti, Francesca ^b,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LAVAL UNIVERSITY   (Canada)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

Bioluminescence imaging; Dexamethasone; Microglia; TLR2; TLR4; synuclein

Indexed keywords

ADAPTOR PROTEIN; ALPHA SYNUCLEIN; DEXAMETHASONE; DNA; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MYELOID DIFFERENTIATION FACTOR 88; PROTEINASE K; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; ANTIPARKINSON AGENT; SNCA PROTEIN, HUMAN; TLR2 PROTEIN, HUMAN; TLR2 PROTEIN, MOUSE; TLR4 PROTEIN, HUMAN; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BIOLUMINESCENCE; BLOOD SAMPLING; BRAIN LEVEL; BRAIN TISSUE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CONVALESCENCE; CORPUS STRIATUM; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FEMALE; FLOW CYTOMETRY; FUNCTIONAL ASSESSMENT; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNE SYSTEM; INNATE IMMUNITY; LONGITUDINAL STUDY; MALE; MICROGLIA; MIDDLE AGED; MONOCYTE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PUTAMEN; REPORTER GENE; VERY ELDERLY; WESTERN BLOTTING; WHEEL RUNNING ACTIVITY TEST; ANIMAL; BLOOD; BRAIN; C57BL MOUSE; CASE CONTROL STUDY; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; TIME FACTOR; TRANSGENIC MOUSE; UPREGULATION;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANIMALS; ANTIPARKINSON AGENTS; B-LYMPHOCYTES; BRAIN; CASE-CONTROL STUDIES; DEXAMETHASONE; DISEASE MODELS, ANIMAL; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; MIDDLE AGED; MONOCYTES; PARKINSON DISEASE; TIME FACTORS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; UP-REGULATION;

EID: 84939213691     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu103     Document Type: Article

References (59)

1. Anderson DC, Cranford RE (1979) Corticosteroids in ischemic stroke. Stroke 10:68-71.
2. Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T (2005) Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 11:493-498.
3. Bas J, Calopa M, Mestre M, Mollevi DG, Cutillas B, Ambrosio S, Buendia E (2001) Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol 113:146-152.
4. Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, Loeschke S, Bullerdiek J (2008) Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer 47:56-63.
5. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202:17-20.
6. Brudek T, Winge K, Agander TK, Pakkenberg B (2013) Screening of Toll-like receptors expression in multiple system atrophy brains. Neurochem Res 38:1252-1259.
7. Castano A, Herrera AJ, Cano J, Machado A (2002) The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh- TNF-alpha, IL-1beta and IFN-gamma. J Neurochem 81:150-157.
8. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364:1167-1169.
9. Chesselet MF, Richter F (2011) Modelling of Parkinson's disease in mice. Lancet Neurol 10:1108-1118.
10. Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR (2012) A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics 9:297-314.
11. Cote M, Drouin-Ouellet J, Cicchetti F, Soulet D (2011) The critical role of the MyD88-dependent pathway in non-CNS MPTPmediated toxicity. Brain Behav Immun 25:1143-1152.
12. Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB (2005) Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation 2:14.
13. Drouin-Ouellet J, Gibrat C, Bousquet M, Calon F, Kriz J, Cicchetti F (2011) The role of the MYD88-dependent pathway in MPTPinduced brain dopaminergic degeneration. J Neuroinflammation 8:137.
14. Drouin-Ouellet J, Cicchetti F (2012) Inflammation and neurodegeneration: the story 'retolled'. Trends Pharmacol Sci 33:542- 551.
15. Drouin-Ouellet J, LeBel M, Filali M, Cicchetti F (2012) MyD88 deficiency results in both cognitive and motor impairments in mice. Brain Behav Immun 26:880-885.
16. Dunne A, O'Neill LA (2003) The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003:re3.
17. Fernagut PO, Hutson CB, Fleming SM, Tetreaut NA, Salcedo J, Masliah E, Chesselet MF (2007) Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 61:991-1001.
18. Frisancho-Kiss S, Davis SE, Nyland JF, Frisancho JA, Cihakova D, Barrett MA, Rose NR, Fairweather D (2007) Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol 178:6710-6714.
19. Funk N, Wieghofer P, Grimm S, Schaefer R, Buhring HJ, Gasser T, Biskup S (2013) Characterization of peripheral hematopoietic stem cells and monocytes in Parkinson's disease. Mov Disord 28:392-395.
20. Gardai SJ, Mao W, Schule B, Babcock M, Schoebel S, Lorenzana C, Alexander J, Kim S, Glick H, Hilton K, Fitzgerald JK, Buttini M, Chiou SS, McConlogue L, Anderson JP, Schenk DB, Bard F, Langston JW, Yednock T, Johnston JA (2013) Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One 8:e71634.
21. Grage-Griebenow E, Lorenzen D, Fetting R, Flad HD, Ernst M (1993) Phenotypical and functional characterization of Fc gamma receptor I (CD64)-negative monocytes, a minor human monocyte subpopulation with high accessory and antiviral activity. Eur J Immunol 23:3126-3135.
22. Han KJ, Yang Y, Xu LG, Shu HB (2010) Analysis of a TIR-less splice variant of TRIF reveals an unexpected mechanism of TLR3- mediated signaling. J Biol Chem 285:12543-12550.
23. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184.
24. Jagannathan M, Hasturk H, Liang Y, Shin H, Hetzel JT, Kantarci A, Rubin D, McDonnell ME, Van Dyke TE, Ganley-Leal LM, Nikolajczyk BS (2009) TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. J Immunol 183:7461-7470.
25. Kim C Ho, DH Suk, JE You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee HJ, Lee SJ (2013) Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 4:1562.
26. Kim C, Cho ED, Kim HK, You S, Lee HJ, Hwang D, Lee SJ (2014) beta1-integrin-dependent migration of microglia in response to neuron-released alpha-synuclein. Exp Mol Med 46:e91.
27. Kudo T, Loh DH, Truong D, Wu Y, Colwell CS (2011) Circadian dysfunction in a mouse model of Parkinson's disease. Exp Neurol 232:66-75.
28. Lalancette-Hebert M, Phaneuf D, Soucy G, Weng YC, Kriz J (2009) Live imaging of Toll-like receptor 2 response in cerebral ischaemia reveals a role of olfactory bulb microglia as modulators of inflammation. Brain 132:940-954.
29. Lang AE, Lozano AM (1998) Parkinson's disease. First of two parts. N Engl J Med 339:1044-1053.
30. Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, Kim WK, Junn E, Kim HS (2010) Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 185:615-623.
31. Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, Schulz- Schaeffer W, Fassbender K (2009) Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging 30:759-768.
32. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285-1291.
33. McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10 Suppl 1:S3-S7.
34. Minghetti L, Nicolini A, Polazzi E, Greco A, Perretti M, Parente L, Levi G (1999) Down-regulation of microglial cyclo-oxygenase- 2 and inducible nitric oxide synthase expression by lipocortin 1. Br J Pharmacol 126:1307-1314.
35. Niwa F, Kuriyama N, Nakagawa M, Imanishi J (2012) Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. Geriatr Gerontol Int 12:102- 107.
36. Norris JW, Hachinski VC (1986) High dose steroid treatment in cerebral infarction. Br Med J (Clin Res Ed) 292:21-23.
37. Ouchi Y, Yoshikawa E Sekine, Y Futatsubashi, M Kanno, T Ogusu, T Torizuka (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57:168-175.
38. Panaro MA, Lofrumento DD, Saponaro C, De Nuccio F, Cianciulli A, Mitolo V, Nicolardi G (2008) Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease. Immunopharmacol Immunotoxicol 30:729-740.
39. Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, Feng T, Lee M, Asinovski N, Frohlich I, Imboywa S, Von Korff A, Okada Y, Patsopoulos NA, Davis S, McCabe C, Paik HI, Srivastava GP, Raychaudhuri S, Hafler DA, Koller D, Regev A, Hacohen N, Mathis D, Benoist C, Stranger BE, De Jager PL (2014) Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344:519-523.
40. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE (2009) CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}- stimulated microglial activation. J Neurosci 29:11982-11992.
41. Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, Tsoutsou A, Boufidou F, Kapaki E, Vassilopoulos D (2009) Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol Scand 119:332-337.
42. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68:568-578.
43. Ros-Bernal F, Hunot S, Herrero MT, Parnadeau S, Corvol JC, Lu L, Alvarez-Fischer D, Carrillo-de Sauvage MA, Saurini F, Coussieu C, Kinugawa K, Prigent A, Hoglinger G, Hamon M, Tronche F, Hirsch EC, Vyas S (2011) Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci U S A 108:6632-6637.
44. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn- Hardy K (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302:841.
45. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839-840.
46. Stefanova N, Reindl M, Neumann M, Kahle PJ, Poewe W, Wenning GK (2007) Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord 22:2196-2203.
47. Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK (2011) Toll-like receptor 4 promotes alpha-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol 179:954-963.
48. Stevens CH, Rowe D, Morel-Kopp MC, Orr C, Russell T, Ranola M, Ward C, Halliday GM (2012) Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol 252:95-99.
49. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ (2008) Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 29:1690-1701.
50. Szaflarska A, Baj-Krzyworzeka M, Siedlar M, Weglarczyk K, Ruggiero I, Hajto B, Zembala M (2004) Antitumor response of CD14+/CD16+ monocyte subpopulation. Exp Hematol 32:748-755.
51. Theodore S, Cao S, McLean PJ, Standaert DG (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol, 67:1149-1158.
52. Tremblay C, Pilote M, Phivilay A, Emond V, Bennett DA, Calon F (2007) Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 12:377-390.
53. Tremblay C, St-Amour I, Schneider J, Bennett DA, Calon F (2011) Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol 70:788-798.
54. Ward JR, Francis SE, Marsden L, Suddason T, Lord GM, Dower SK, Crossman DC, Sabroe I (2009) A central role for monocytes in Toll-like receptor-mediated activation of the vasculature. Immunology 128:58-68.
55. Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, Effros RB, Chesselet MF (2012) Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol 237:318-334.
56. West AP, Koblansky AA, Ghosh S (2006) Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol 22:409-437.
57. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J (2005) Aggregated alphasynuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19:533-542.
58. Ziegler-Heitbrock L, Hofer TP (2013) Toward a refined definition of monocyte subsets. Front Immunol 4:23.
59. Ziegler-Heitbrock HW, Appl B, Kafferlein E, Loffler T, Jahn-Henninger H, Gutensohn W, Nores JR, McCullough K, Passlick B, Labeta MO, et al. (1994) The antibody MY4 recognizes CD14 on porcine monocytes and macrophages. Scand J Immunol 40:509-514.